Prognostic value of CA 19‐9 kinetics during gemcitabine‐based chemotherapy in patients with advanced cholangiocarcinoma

Abstract

CA 19-9 but not CEA kinetics serves as a predictor of better survival in patients with advanced CCA on gemcitabine-based chemotherapy. A ≥ 50% decline in CA 19-9 level after two cycles of chemotherapy may have clinical utility as an early indicator of better response to gemcitabine-based chemotherapy.